Researchers have identified a set of genes that could eventually enable humans to regrow lost limbs, marking a significant shift in how scientists approach regenerative medicine. The discovery, published in the Proceedings of the National Academy of Sciences, emerged from a rare collaboration comparing how three different species recover from injury.
The team examined axolotls, zebrafish, and mice because each offered distinct biological advantages. Axolotls can regrow entire limbs, tails, and even portions of organs like the heart and brain. Zebrafish can repeatedly regenerate damaged fins and repair critical tissues including the heart, spinal cord, and pancreas. Mice, like humans, are mammals capable of limited digit regeneration at the fingertip level.
Josh Currie, an assistant professor of biology at Wake Forest University, led the axolotl research alongside collaborators David A. Brown at Duke University and Kenneth D. Poss at the University of Wisconsin-Madison. Currie explained that the three labs discovered something unexpected: "There are universal, unifying genetic programs that are driving regeneration in very different types of organisms."
The breakthrough centers on two genes called SP6 and SP8. When researchers examined regenerating skin tissue across all three species, they found both genes activated during the healing process. To understand their role, Currie's team used CRISPR gene-editing technology to remove SP8 from axolotls. The results were striking. Without the gene, the salamanders could not properly regenerate limb bones.
The same pattern held in mice. When SP6 and SP8 were deleted from regenerating digits, bone regrowth failed. These experiments revealed that SP8 acts as a crucial switch for limb regeneration, triggering the cellular machinery needed to rebuild lost tissue.
Brown's lab then took the next step. They designed a viral gene therapy that delivered a signaling molecule called FGF8, a chemical messenger normally activated by SP8. When administered to injured mouse digits, the treatment encouraged bone regrowth and partially restored regenerative abilities in animals missing the SP genes.
The findings arrive at a moment of growing need. More than one million amputations occur globally each year due to diabetes, traumatic injury, infection, and cancer. That number is expected to rise as populations age and diabetes becomes more prevalent.
Currie cautioned that the work remains in early stages. Jumping from mice to human therapies would require extensive additional research. But he framed the results as a proof of concept for a new therapeutic approach. "We can use this as a kind of proof of principle that we might be able to deliver therapies to substitute for this regenerative style of epidermis in regrowing tissue in humans," he said.
The research also underscores the value of cross-species collaboration. Currie noted that scientists often work in isolation, focusing only on their chosen organism. This project's strength lay in examining the same regenerative problem across three vastly different animals, revealing that evolution had settled on similar genetic solutions.
Future human limb regeneration will likely require multiple approaches, Currie suggested. Bioengineered scaffolds and stem cell therapies are already being pursued. Gene therapy targeting SP genes offers a complementary path that could work alongside these other strategies.
Author Jessica Williams: "This isn't a cure announced today, but it's the kind of fundamental genetic detective work that actually moves the needle on seemingly impossible problems."
Comments